A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy.

ABSTRACT: Chemotherapy is considered the nonsurgical treatment of choice for colon cancer patients. However, no precise molecular markers are available to determine which patients can actually benefit from it. In this study, we identified 55 chemotherapy-specific long non-coding RNAs (lncRNAs) of colon cancer patients through a systematic assessment of lncRNA expression profiles from a public database. These were taken from multiple cohorts of colon cancer patients who had received chemotherapy, or not. Based on these data, a chemoresistance lncRNA signature, named CRLSig, was constructed and successfully applied to divide chemotherapy patients into two groups with different recurrence-free survival (RFS) rates. Gene set enrichment analysis revealed that patients with low CRLSig had more infiltratin

SUBMITTER: Wang H 

PROVIDER: S-EPMC8733234 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature